↑ 疾患リストへ ← 戻る

 211. 左心低形成症候群 [臨床試験数:16,薬物数:16(DrugBank:7),標的遺伝子数:3,標的パスウェイ数:3] 

Searched query = "Hypoplastic left heart syndrome", "Single ventricular circulation syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03406884June 202011 November 2019Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.Hypoplastic Left Heart SyndromeDrug: c-kit+ cells;Drug: PlaceboJoshua M HareUniversity of Maryland, College ParkNot recruitingN/A27 DaysAll30Phase 1United States
2NCT04090697November 1, 201930 September 2019Use of Oxandrolone to Promote Growth in Infants With HLHSUse of Oxandrolone to Promote Growth in Infants With Hypoplastic Left Heart Syndrome: A Phase I/II Pilot StudyHypoplastic Left Heart;Congenital Heart DiseaseDrug: OxandroloneNew England Research InstitutesNot recruitingN/A14 DaysAll100Phase 1/Phase 2
3NCT03779711April 201925 March 2019Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome (AutoCell-S2)Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2)Hypoplastic Left Heart SyndromeBiological: Autologous (self) mononuclear cells derived from umbilical cord blood;Procedure: Stage II Surgical repairTimothy J. NelsonUniversity of Oklahoma;Children's Hospital of Philadelphia;Children's Hospital Los Angeles;Children's Hospital Colorado;Children's Hospitals and Clinics of MinnesotaRecruitingN/A8 MonthsAll100Phase 2United States
4NCT03525418February 21, 201815 October 2018Longeveron Mesenchymal Stem Cells (LMSCs) Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)Allogeneic Human MEsenchymal Stem Cell (MSC) Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)HLHSBiological: Longeveron Mesenchymal Stem CellsLongeveron LLCRecruitingN/A1 YearAll30Phase 1/Phase 2United States
5NCT03431480February 16, 20186 May 2019Safety of Autologous Cord Blood Cells in HLHS Patients During Norwood Heart SurgerySafety Study of Autologous Cord Blood Stem Cell Treatment in Hypoplastic Left Heart Syndrome Patients Undergoing the Norwood Heart OperationHypoplastic Left Heart Syndrome;Heart Defects, Congenital;Pediatric DisorderBiological: Autologous Human Placental Cord Blood Mononuclear CellsMurdoch Childrens Research InstituteRecruitingN/A4 DaysAll12Phase 1Australia
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03136835February 2, 201810 September 2018Maternal Hyperoxygenation in Congenital Heart DiseaseMaternal Hyperoxygenation in Congenital Heart DiseaseHypoplastic Left Heart SyndromeDrug: Maternal HyperoxygenationThe Hospital for Sick ChildrenRecruiting18 YearsN/AFemale20Phase 1/Phase 2Canada
7NCT03147014January 1, 201618 December 2018Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart DiseaseCardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart DiseaseHypoplastic Left Heart Syndrome;Aortic Coarctation;Atrial Septal AneurysmBiological: Maternal hyperoxygenationBeijing Anzhen HospitalRecruitingN/AN/AFemale600N/AChina
8NCT02080637July 201511 June 2018Ambrisentan in Single VentricleSafety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric PatientsHypoplastic Left Heart Syndrome;Hypoplastic Right-sided Heart ComplexDrug: Ambrisentan;Other: PlaceboKevin HillNot recruiting24 Months120 MonthsAll20Phase 2United States
9JPRN-UMIN0000173112015/05/0121 May 2019Hypoxia inhalation therapy for infants with pulmonary congestion caused by congenital heart disease.Hypoxia inhalation therapy for infants with pulmonary congestion caused by congenital heart disease. - Hypoxia inhalation therapy for infantshypoplastic left heart syndrome, coarctation of aorta, interruption of aorta, truncus arteriosus, double outlet of right ventricle (Taussig-Bing anomaly), single ventriclesHypoxia inhalation
nitrogen inhalation
Institutional Review Board of Kagoshima UniversityNot Recruiting1days-old365days-oldMale and Female30Not selectedJapan
10NCT02398604April 201515 July 2019Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart SyndromeAllogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.Hypoplastic Left Heart SyndromeDrug: Allo-hMSCs;Drug: PlaceboJoshua M HareUniversity of MarylandNot recruitingN/A30 DaysAll5Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01883076May 15, 201325 March 2019Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart SyndromePhase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart SyndromeHypoplastic Left Heart SyndromeBiological: autologous cell-based deliveryTimothy J. NelsonUniversity of Oklahoma;Children's Hospital of Philadelphia;Children's Hospitals and Clinics of Minnesota;Children's Hospital Los Angeles;Children's Hospital ColoradoRecruitingN/A18 MonthsAll30Phase 1United States
12NCT01445041September 201115 July 2019Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart SyndromeAutologous Cord Blood Cells for Patients With HLHS: Phase I Study of Feasibility and SafetyHypoplastic Left Heart SyndromeBiological: Autologous Umbilical Cord BloodMichael CottenNot recruitingN/A2 DaysAll20Phase 1United States
13EUCTR2010-022389-28-DK12/11/201012 May 2014Treatment with Endothelinantagonist to tcpc patients; a multicenter, randomized, Prospective study measuring maximal O2 uptake in ergometer bicycle test. [TEMPO-study].Treatment with Endothelinantagonist to tcpc patients; a multicenter, randomized, Prospective study measuring maximal O2 uptake in ergometer bicycle test. [TEMPO-study].Patients with a univentricular heart, who have recieved paliating surgery in the form of TCPC operation
MedDRA version: 14.1 Level: PT Classification code 10021076 Term: Hypoplastic left heart syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: Tracleer
Pharmaceutical Form:
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Lars SøndergaardNot RecruitingFemale: yes
Male: yes
Denmark
14NCT00974025June 200916 December 2017Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated PatientsVitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan PalliationFontan Procedure;Hypoplastic Left Heart Syndrome;Tricuspid AtresiaDietary Supplement: Vitamin C;Dietary Supplement: PlaceboUniversity of MichiganGriese-Hutchinson Champions for Children's Hearts Investigator AwardNot recruiting8 Years25 YearsAll53N/AUnited States
15NCT00507819December 200719 October 2017Sildenafil After the Fontan OperationThe Sildenafil After Fontan Operation StudyHypoplastic Left Heart Syndrome;Tricuspid AtresiaDrug: Sildenafil;Drug: PlaceboChildren's Hospital of PhiladelphiaThe Mark H. and Blanche M. Harrington FoundationNot recruiting8 Years40 YearsAll28Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00513240September 200619 October 2017Erythropoetin Neuroprotection for Neonatal Cardiac SurgeryErythropoetin Neuroprotection for Neonatal Cardiac SurgeryCongenital Heart Disease;Hypoplastic Left Heart Syndrome;Transposition of the Great Arteries;Aortic Arch Hypoplasia or InterruptionDrug: Erythropoetin;Drug: Normal salineBaylor College of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);The Dana Foundation;Texas Children's HospitalNot recruitingN/A30 DaysAll62Phase 1/Phase 2United States

先頭へ